[Ip-health] Survey: US Health Agency Should Use Patent Rights To Keep Drugs Affordable
Biotech. Info. Inst.
biotech at biopharma.com
Wed Sep 4 13:35:19 PDT 2013
Most everyone reading this likely has strong opinions on the these topics. My questions, like the topic, concerned what is the state of U.S. general public knowledge and opinion.
So, are there any recent survey, polling or other data concerning U.S. public (or health care professionals') knowledge and attitudes towards NIH pharmaceutical product-related patent licensing, related 'reasonable pricing' issues, etc.?" I vaguely recall there were some such data way back (in the early-mid 1990s?) when 'reasonable pricing' for pharmaceuticals resulting from NIH CRADAs was a hot topic.
Ronald A. Rader
Biotechnology Information Institute
1700 Rockville Pike, Suite 400
Rockville, MD 20852
E-mail: biotech at biopharma.com
Web sites: www.biopharma.com; www.bioinfo.com
On Sep 4, 2013, at 1:23 PM, Jamie Love <james.love at keionline.org> wrote:
> Ronald Rader,
> If the NIH funds the R&D for a new drug, it seems both unreasonable and appalling to me that US consumers would pay more for that drug than is charged in other high income countries. I personally don't think that extends to prices in lower income countries, where I hope that prices are lower. The Survey responses show that a very large proporiation of the public shares our view, as regards pricing of NIH funded drugs in high income countries.
> If the US imposes reference pricing oblgiations on NIH funded drugs, it would be easy to administer, and not require anything in particular as regards foreign prices, but it would protect US consumers from paying more, when they have already subdizied the development of the R&D, *AND* have rights in the patented inventions. I believe this set of facts applies to about 7 percent of FDA approved drugs, over the past five years, so it is not going to solve all problems as regards drug pricing, but it will impact one significant and important set of drugs.
> You can create all sorts of other policy questions to vet or survey, of course. But this is one that we are focusing on right now.
More information about the Ip-health